51. Gout
ACR on Air
00:00
Phaboxastat: A Review
The CARES trial published about four years ago now had a major impact, demonstrated increased or caused an increased cardiovascular mortality in that trial with phaboxastat compared to allopurinol. There now been two additional trials, which I think have provided a lot more reassurance around this. The FAST trial, which was essentially the EMA equivalent to CARES published in the Lancet, actually showed no safety signal with phabOxastat and if anything, a slightly lower risk of cardiovascular events and mortality compared with allopURinol. And then also importantly, the VA stop-gout study, which was just published a year or so ago now, again, a
Transcript
Play full episode
